osimertinib
astrazeneca
['osimertinib']
adjuvant osimertinib with long-term survival benefit confirmed. now can insurances start letting us do ngs testing for these patients? we need to know what these patients genomic profile is. it will change lives. #asco23. #nomorep2p 
Jeff Yorio, MD is a practicing medical oncologist and hematologist at Texas Oncology in Austin, Texas.  He is actively involved in clinical trials in Austin.